Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
MWN-AI** Summary
Clearmind Medicine Inc. (Nasdaq: CMND), a Vancouver-based clinical-stage biotech company, recently announced that the independent Data and Safety Monitoring Board (DSMB) has provided a positive recommendation to continue the ongoing Phase I/IIa clinical trial for CMND-100, aimed at treating Alcohol Use Disorder (AUD). The DSMB's endorsement follows the successful completion of the third cohort in the trial, where CMND-100 demonstrated encouraging safety data, showing it was well tolerated among participants with no serious adverse events reported.
These results align with the positive safety profile observed in earlier cohorts, allowing Clearmind to move forward to the fourth cohort, where the dosage of CMND-100, a non-hallucinogenic MEAI-based oral candidate, will be increased to 160mg. This clinical trial, which spans multiple countries and centers, focuses on evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients suffering from moderate to severe AUD.
Clearmind is committed to developing neuroplastogen-derived therapeutics to address significant and under-treated health issues, particularly those related to alcohol use. The company holds an extensive intellectual property portfolio, with 31 granted patents across 19 families and aims to continue expanding this portfolio through further patent acquisitions.
As Clearmind Medicine makes strides in its clinical trials for CMND-100, investors might look favorably on the company's progress in addressing AUD, a condition that affects millions. Clearmind's shares are publicly traded on the Nasdaq under the ticker "CMND," and more information can be found on their website. The announcement underscores the potential for innovative treatments in the realm of addiction and mental health, positioning Clearmind as a key player in this emerging biotech sector.
MWN-AI** Analysis
Clearmind Medicine Inc. (Nasdaq: CMND) recently announced a positive recommendation from its independent Data and Safety Monitoring Board (DSMB), allowing the continuation of the CMND-100 clinical trial aimed at treating Alcohol Use Disorder (AUD). This development, along with the reassuring safety data reported from the third cohort reflects strong progress for the company, bolstering investor confidence in its clinical pipeline.
As Clearmind advances to the fourth cohort of the FDA-approved Phase I/IIa trial, increasing the dosage of CMND-100, investors should consider several factors. The drug's positive safety profile, free from serious adverse events, signifies a pivotal advancement in a market that increasingly demands effective, non-hallucinogenic treatments for AUD. Given the growing regulatory acceptance of psychedelic-assisted therapeutics, Clearmind's focus on neuroplastogens positions it favorably within a burgeoning sector.
Evaluating Clearmind’s stock performance post-announcement will reveal vital investor sentiment. Historically, positive clinical trial updates have often led to price increases; however, sustaining momentum will depend on future cohort results and continued transparency from the management regarding the trial's progression.
Investors should also observe Clearmind's intellectual property strategy, as the robust portfolio of nineteen patent families illustrates a commitment to protecting its innovations. As the company seeks to expand its IP assets, potential partnerships or licensing agreements could emerge, enhancing revenue streams.
That said, the biotechnology sector is inherently volatile. Investors must remain cautious of the risks outlined in Clearmind's filings with the SEC, particularly regarding trial success and market competition. In summary, Clearmind represents a speculative but potentially rewarding investment opportunity, particularly for those with an appetite for emerging biotech firms focused on unmet medical needs in mental health.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vancouver, Canada, April 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that its independent Data and Safety Monitoring Board (“DSMB”) has completed its review and issued a positive recommendation to continue the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100 for the treatment of Alcohol Use Disorder (“AUD”).
The positive DSMB recommendation follows the successful completion of the third cohort and is based on encouraging top-line safety data demonstrating that CMND-100 was well tolerated with no serious adverse events reported. These results reinforce the favorable safety and tolerability profile observed in previous cohorts.
As a result, the Company will now proceed to the fourth cohort of the trial and will increase the tested dose of its proprietary drug candidate CMND-100 to 160mg.
The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, in patients with moderate to severe AUD.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ**
Given the ongoing FDA-approved Phase I/IIa clinical trial, how is Clearmind Medicine Inc. CMND planning to manage potential risks related to the safety profile of CMND-100 as they advance to the fourth cohort?
What strategies are in place for Clearmind Medicine Inc. CMND to address the intellectual property landscape surrounding its proprietary drug candidate CMND-100 and ensure market exclusivity?
How does Clearmind Medicine Inc. CMND plan to leverage the positive recommendation from the Data and Safety Monitoring Board to enhance investor confidence and secure further funding for future trials?
With Clearmind Medicine Inc. CMND focusing on non-hallucinogenic therapeutics for Alcohol Use Disorder, what other health problems is the company considering addressing through its neuroplastogen-derived compounds?
**MWN-AI FAQ is based on asking OpenAI questions about Clearmind Medicine Inc. (NASDAQ: CMND).
NASDAQ: CMND
CMND Trading
41.04% G/L:
$3.53 Last:
41,970,858 Volume:
$3.49 Open:
